<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9320">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05700513</url>
  </required_header>
  <id_info>
    <org_study_id>70746</org_study_id>
    <nct_id>NCT05700513</nct_id>
  </id_info>
  <brief_title>Dog-rose, Cranberry Leaves, Cranberry Berries, Alfalfa, Fenugreek, Lemon Beebrush, Urtica and Sumac in Diabetes Mellitus</brief_title>
  <official_title>The Joint Effects of Dog-rose, Cranberry Leaves, Cranberry Berries, Alfalfa, Fenugreek, Lemon Beebrush, Urtica, and Sumac for Controlling Blood Glucose of Patients With Type II Diabetes Mellitus: A Phase 1-2 Randomized Placebo-Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tabriz University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tabriz University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates the safety and combined effect of Cranberry leaves, Cranberry&#xD;
      Berries, Alfalfa, Fenugreek, Lemon Beebrush, Urtica, Dog-rose, and Sumac on improving the&#xD;
      glycemic profile of patients with type 2 diabetes mellitus compared to the placebo group.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The present double-blind, randomized and placebo-controlled study will be conducted on type 2&#xD;
      diabetes mellitus patients to evaluate the safety and combined effect of Cranberry leaves,&#xD;
      Cranberry Berries, Alfalfa, Fenugreek, Lemon Beebrush, Urtica, Dog-rose, and Sumac on&#xD;
      improving glycemic profiles (fasting blood sugar, glycosylated Hemoglobin, 2 hours&#xD;
      postprandial blood sugar, insulin concentration, insulin resistance, and beta-cell function).&#xD;
      The study also evaluates systolic blood pressure, diastolic blood pressure, anthropometric&#xD;
      variables, lipid profile, C-reactive protein, and renal and liver function tests.&#xD;
&#xD;
      A pilot study with 30 participants will be conducted to estimate the sample size considering&#xD;
      0.05 first type error and a power of 80%. Individuals aged between 18-70 with a diagnosis of&#xD;
      type 2 diabetes mellitus based on WHO criteria for at least one year will be enrolled.&#xD;
      Participants will be randomized in the placebo or intervention group to receive two capsules&#xD;
      per day before lunch and dinner for six months containing 200 milligrams of equally combined&#xD;
      extracts of Cranberry leaves, Cranberry Berries, Alfalfa, Fenugreek, Lemon Beebrush, Urtica,&#xD;
      Dog-rose, and Sumac. Participants will be followed up with four office visits (t0= baseline,&#xD;
      1=15th day, 2t=3rd month, 3t=6th month) to assess outcomes. Also, the complications and&#xD;
      adherence of patients to intervention will be checked every two weeks by telephonic&#xD;
      discussion. The analysis will be performed based on the intent-to-treat method.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 28, 2023</start_date>
  <completion_date type="Anticipated">February 28, 2025</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fasting blood glucose</measure>
    <time_frame>Day 0, 15, 90, 180 post intervention</time_frame>
    <description>Change in fasting blood glucose in response to intervention</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulin level</measure>
    <time_frame>Day 0, 15, 90, 180 post intervention</time_frame>
    <description>Change in insulin level in response to intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin A1c level</measure>
    <time_frame>Day 0, 15, 90, 180 post intervention</time_frame>
    <description>Change in hemoglobin A1c level in response to intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High density lipoprotein (HDL) level</measure>
    <time_frame>Day 0, 15, 90, 180 post intervention</time_frame>
    <description>Change in high density lipoprotein (HDL) level in response to intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low density lipoprotein (LDL) level</measure>
    <time_frame>Day 0, 15, 90, 180 post intervention</time_frame>
    <description>Change in low density lipoprotein (LDL) level in response to intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglyceride level</measure>
    <time_frame>Day 0, 15, 90, 180 post intervention</time_frame>
    <description>Change in triglyceride level in response to intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total cholesterol level</measure>
    <time_frame>Day 0, 15, 90, 180 post intervention</time_frame>
    <description>Change in total cholesterol level in response to intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aspartate transaminase level</measure>
    <time_frame>Day 0, 15, 90, 180 post intervention</time_frame>
    <description>Change in aspartate transaminase level in response to intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alanine aminotransferase level</measure>
    <time_frame>Day 0, 15, 90, 180 post intervention</time_frame>
    <description>Change in alanine aminotransferase level in response to intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood urea nitrogen level</measure>
    <time_frame>Day 0, 15, 90, 180 post intervention</time_frame>
    <description>Change in blood urea nitrogen level in response to intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine level</measure>
    <time_frame>Day 0, 15, 90, 180 post intervention</time_frame>
    <description>Change in creatinine level in response to intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prothrombin time</measure>
    <time_frame>Day 0, 15, 90, 180 post intervention</time_frame>
    <description>Change in prothrombin time in response to intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bilirubin level</measure>
    <time_frame>Day 0, 15, 90, 180 post intervention</time_frame>
    <description>Change in bilirubin level in response to intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ferritin level</measure>
    <time_frame>Day 0, 15, 90, 180 post intervention</time_frame>
    <description>Change in ferritin level in response to intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cholinesterase level</measure>
    <time_frame>Day 0, 15, 90, 180 post intervention</time_frame>
    <description>Change in cholinesterase level in response to intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High-sensitivity C-reactive protein level</measure>
    <time_frame>Day 0, 15, 90, 180 post intervention</time_frame>
    <description>Change in high-sensitivity C-reactive protein level in response to intervention</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Capsules containing the combination products</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Capsules containing dog-rose, Cranberry leaves, Cranberry Berries, Alfalfa, Fenugreek, Lemon Beebrush, Urtica, and Sumac</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsules containing maltodextrin</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Capsules containing the combination products</intervention_name>
    <description>Capsules containing dog-rose, Cranberry leaves, Cranberry Berries, Alfalfa, Fenugreek, Lemon Beebrush, Urtica, and Sumac</description>
    <arm_group_label>Capsules containing the combination products</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo capsules</intervention_name>
    <description>Placebo capsules containing maltodextrin</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  At least one year of diagnosis of type 2 diabetes according to the criteria of the&#xD;
             World Health Organization,&#xD;
&#xD;
          -  Hemoglobin A1c (HbA1c) &gt; 7.0% or fasting blood glucose &gt; 7.0 mmol/L,&#xD;
&#xD;
          -  Body mass index (BMI) more than 23 kg/m2 and less than 35.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Comorbidities, including type 1 diabetes, cardiovascular disease, thyroid disease,&#xD;
             liver disease, kidney disease, cancer, mental disorders, and the use of drugs related&#xD;
             to the aforementioned diseases,&#xD;
&#xD;
          -  Pregnancy,&#xD;
&#xD;
          -  Patients with a BMI over 35 who were on a weight loss diet or had taken weight loss&#xD;
             supplements for less than 6 months&#xD;
&#xD;
          -  A history of allergy to one of the components of the nestling fruit, carob leaf, carob&#xD;
             fruit, alfalfa seed, fenugreek seed, lemon, Nettles and sumac and also&#xD;
&#xD;
          -  Lactating women&#xD;
&#xD;
          -  Regularly consuming cigarettes or alcohol&#xD;
&#xD;
          -  Using psychiatric drugs or insulin&#xD;
&#xD;
          -  Changing in the medication regimen during the trial period. For example, to start&#xD;
             receiving insulin therapy, become pregnant, or no longer follow medication and dietary&#xD;
             instructions.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Saeid Safiri, PhD</last_name>
    <phone>+984133342178</phone>
    <email>saeidsafiri@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Imam Reza hospital and clinic of Salamat</name>
      <address>
        <city>Tabriz</city>
        <state>AzarbayejaneShargi</state>
        <zip>5166614766</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>April 2023</verification_date>
  <study_first_submitted>January 17, 2023</study_first_submitted>
  <study_first_submitted_qc>January 17, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 26, 2023</study_first_posted>
  <last_update_submitted>April 11, 2023</last_update_submitted>
  <last_update_submitted_qc>April 11, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tabriz University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Dr. Saeid Safiri</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Type 2 diabetes</keyword>
  <keyword>Insulin resistance</keyword>
  <keyword>Lipochromin</keyword>
  <keyword>Vaccinium macrocarpon</keyword>
  <keyword>Medicago sativa</keyword>
  <keyword>Trigonella</keyword>
  <keyword>Fenugreek</keyword>
  <keyword>Lemon Beebrush</keyword>
  <keyword>Urtica dioica</keyword>
  <keyword>Rhus</keyword>
  <keyword>Sumac</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

